Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP427414.RAS_2dmwTzsbTmZ94CjB7-ntdk2ruKDMG7ofjE4-U2WK4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP427414.RAS_2dmwTzsbTmZ94CjB7-ntdk2ruKDMG7ofjE4-U2WK4130_assertion type Assertion NP427414.RAS_2dmwTzsbTmZ94CjB7-ntdk2ruKDMG7ofjE4-U2WK4130_head.
- NP427414.RAS_2dmwTzsbTmZ94CjB7-ntdk2ruKDMG7ofjE4-U2WK4130_assertion description "[Combined neoadjuvant trastuzumab and docetaxel induced high clinical response rates for HER2-overexpressing breast cancer, in particular for inflammatory breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP427414.RAS_2dmwTzsbTmZ94CjB7-ntdk2ruKDMG7ofjE4-U2WK4130_provenance.
- NP427414.RAS_2dmwTzsbTmZ94CjB7-ntdk2ruKDMG7ofjE4-U2WK4130_assertion evidence source_evidence_literature NP427414.RAS_2dmwTzsbTmZ94CjB7-ntdk2ruKDMG7ofjE4-U2WK4130_provenance.
- NP427414.RAS_2dmwTzsbTmZ94CjB7-ntdk2ruKDMG7ofjE4-U2WK4130_assertion SIO_000772 14715110 NP427414.RAS_2dmwTzsbTmZ94CjB7-ntdk2ruKDMG7ofjE4-U2WK4130_provenance.
- NP427414.RAS_2dmwTzsbTmZ94CjB7-ntdk2ruKDMG7ofjE4-U2WK4130_assertion wasDerivedFrom befree-2016 NP427414.RAS_2dmwTzsbTmZ94CjB7-ntdk2ruKDMG7ofjE4-U2WK4130_provenance.
- NP427414.RAS_2dmwTzsbTmZ94CjB7-ntdk2ruKDMG7ofjE4-U2WK4130_assertion wasGeneratedBy ECO_0000203 NP427414.RAS_2dmwTzsbTmZ94CjB7-ntdk2ruKDMG7ofjE4-U2WK4130_provenance.